Sharemaestro company-news research for XORTX Therapeutics Inc (XRTX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest XRTX news and sentiment

XORTX Therapeutics Inc

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research RSS feed
30-day score50Neutral is 50
Early balanced news score 16/100 evidence confidence 100% direct company focus 24 current stories across 3 publishers
Latest weekly closeUSD 1.92week of 18 Sep 2026
Main news subjectMarket update85/100 share of current news
News data statusPartial17 duplicate stories removed

Current company news

Early balanced news score

24 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone66/100 Published 30-day score50/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis kalkine.com.au · 18 Sep 2026 20:29

What supports the score

Direct evidence

24 current stories are mapped specifically to XRTX.

Source breadth

The score uses 3 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.014.

Confidence

Confidence is 16/100, below the threshold for a firm score.

50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news24 company stories
93/100
Story agreement7/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
27 Aug: 2 stories28 Aug: 2 stories29 Aug: 1 stories01 Sep: 1 stories03 Sep: 1 stories04 Sep: 1 stories05 Sep: 1 stories08 Sep: 1 stories09 Sep: 3 stories10 Sep: 2 stories11 Sep: 3 stories16 Sep: 1 stories18 Sep: 5 stories 27 Aug: tone 50, 2 stories28 Aug: tone 50, 2 stories29 Aug: tone 50, 1 stories01 Sep: tone 71, 1 stories03 Sep: tone 50, 1 stories04 Sep: tone 50, 1 stories05 Sep: tone 57, 1 stories08 Sep: tone 50, 1 stories09 Sep: tone 50, 3 stories10 Sep: tone 50, 2 stories11 Sep: tone 50, 3 stories16 Sep: tone 58, 1 stories18 Sep: tone 50, 5 stories 95505
27 Aug11 Sep25 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence0
0.014 after freshness weighting
Source breadth60
3 independent publishers
Company relevance100
share tied directly to this company
Freshness23
recency-weighted evidence
Agreement93
how closely stories agree
Publisher mix48
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks12 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar 2026: close 1.8955, indexed 100.003 Apr 2026: close 2.1475, indexed 113.310 Apr 2026: close 2.49, indexed 131.417 Apr 2026: close 2.27, indexed 119.824 Apr 2026: close 3.03, indexed 159.901 May 2026: close 2.78, indexed 146.708 May 2026: close 2.79, indexed 147.215 May 2026: close 2.59, indexed 136.622 May 2026: close 2.18, indexed 115.029 May 2026: close 2.3, indexed 121.305 Jun 2026: close 2.21, indexed 116.612 Jun 2026: close 2.18, indexed 115.019 Jun 2026: close 2.09, indexed 110.326 Jun 2026: close 2.19, indexed 115.503 Jul 2026: close 2.07, indexed 109.210 Jul 2026: close 2.175, indexed 114.717 Jul 2026: close 2.01, indexed 106.024 Jul 2026: close 2.025, indexed 106.831 Jul 2026: close 2.12, indexed 111.807 Aug 2026: close 2.13, indexed 112.414 Aug 2026: close 2.155, indexed 113.721 Aug 2026: close 2.04, indexed 107.628 Aug 2026: close 2.338, indexed 123.304 Sep 2026: close 2.31, indexed 121.911 Sep 2026: close 2.33, indexed 122.918 Sep 2026: close 1.92, indexed 101.3 03 Jul 2026: news score 50, close 2.07, 2 stories5010 Jul 2026: news score 50, close 2.175, 5 stories17 Jul 2026: news score 50, close 2.01, 6 stories5024 Jul 2026: news score 49, close 2.025, 10 stories31 Jul 2026: news score 49, close 2.12, 21 stories4907 Aug 2026: news score 52, close 2.13, 28 stories14 Aug 2026: news score 49, close 2.155, 27 stories4921 Aug 2026: news score 48, close 2.04, 26 stories28 Aug 2026: news score 49, close 2.338, 18 stories4904 Sep 2026: news score 52, close 2.31, 12 stories11 Sep 2026: news score 51, close 2.33, 21 stories5118 Sep 2026: news score 51, close 1.92, 24 stories51 Price index 167.0 129.9 92.8 News score 100 50 0
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
26-week price+1.3%latest close 1.92
News score change+1first to latest comparable week
One-week response-17.6%Price reacting lower
Fair-value position-72.7%Below fair value
WeekNews scoreCloseWeekly move
18 Sep 202651USD 1.92-17.6%
11 Sep 202651USD 2.33+0.9%
04 Sep 202652USD 2.31-1.2%
28 Aug 202649USD 2.338+14.6%
21 Aug 202648USD 2.04-5.3%
14 Aug 202649USD 2.155+1.2%
07 Aug 202652USD 2.13+0.5%
31 Jul 202649USD 2.12+4.7%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update5217 stories · 71%
Earnings523 stories · 12%
Deals and strategy503 stories · 12%
Regulatory and legal501 stories · 4%

Source mix

Where the evidence comes from

48/100 independence
Stock Titan504 stories · 17%
kalkine.ca693 stories · 12%
GlobeNewswire503 stories · 12%
TipRanks502 stories · 8%
Value Research502 stories · 8%
Benzinga581 stories · 4%
AD HOC NEWS571 stories · 4%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences12Finance7Financial Markets6Earnings4Manufacturing3

Earlier readings

How the score has changed

35 comparable readings · 87 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+050 to 50 · Broadly stable
Observed range47–5350 is the neutral baseline
Evidence depth24stories at latest stored reading · +23
Confidence16/100Provisional · +16
29 Jun50 neutral25 Sep 10:23
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
25 Sep 10:2350-116/100 (-4)24 (0)Provisional
18 Sep 23:5951+020/100 (-5)24 (+5)Provisional
16 Sep 23:5951+025/100 (+5)19 (-2)Provisional
11 Sep 23:5951+020/100 (-1)21 (+2)Provisional
10 Sep 23:5951+021/100 (0)19 (+2)Provisional
09 Sep 23:5951+021/100 (-1)17 (+3)Provisional
08 Sep 23:5951-122/100 (-5)14 (+1)Provisional
05 Sep 23:5952+027/100 (+1)13 (+1)Provisional

Source headlines

The news behind the score

Showing 1-24 of 24

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
kalkine.com.auDirect company coverageStored article

XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis

This article provides an overview of XORTX Therapeutics Inc (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on hyperuricemia-related diseases. It details their drug pipeline, including treatments for gout, autosomal dominant polycystic kidney disease, acute kidney injury, and type 2 diabetic nephropathy. The company's key financial metrics, income statements, balance sheets, and cash flow breakdowns for recent years are also presented, alongside a peer comparison in the biotechnology sector.

EarningsFinancial MarketsLife Sciences
Published
18 Sep 2026 20:29
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.6d old
Duplicates
1 consolidated
#2—Not directional
StocksToTradeDirect company coverageStored article

XRTX Stock Whipsaws As XORTX Ramps Gout Drug Manufacturing

XORTX Therapeutics Inc. (NASDAQ: XRTX) shares have risen by 13.55% following positive developments for its lead kidney therapy. The company has initiated contract manufacturing for its XRx-026 gout program, moving closer to planned clinical trials and a future New Drug Application. This step, combined with governance clean-up efforts like delisting from TSX Venture Exchange and clarifying finder's fees, positions XRTX as a high-volatility, catalyst-driven stock for active traders.

EarningsFinancial MarketsLife Sciences
Published
18 Sep 2026 16:33
News subject
Earnings
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.7d old
Duplicates
1 consolidated
#3—Not directional
finance.yahoo.comDirect company coverageScored from headline

XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History

Published
18 Sep 2026 12:28
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.9d old
Duplicates
1 consolidated
#4—Not directional
Stock TitanDirect company coverageStored article

A potential new gout pill targets a $700M market as XORTX Therapeutics (XRTX) details its FDA game plan

XORTX Therapeutics Inc. (XRTX) is advancing its XRx-026 gout program, planning an Investigational New Drug (IND) submission to the FDA in Q4 2026 for its XORLO™ formulation of oxypurinol. The company aims for a New Drug Application (NDA) submission approximately one year later, targeting an annual U.S. gout market opportunity of $700 million. XRx-026 is positioned as an alternative for patients who cannot tolerate existing treatments like allopurinol or are affected by febuxostat's cardiovascular warning.

Life Sciences
Published
18 Sep 2026 12:05
News subject
Regulatory and legal
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.9d old
Duplicates
1 consolidated
#5—Not directional
GlobeNewswireDirect company coverageScored from headline

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

Published
18 Sep 2026 12:05
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.9d old
Duplicates
1 consolidated
#658Tone
BenzingaDirect company coverageStored article

XORTX Therapeutics Shares Rise 16.11% After Hours - XORTX Therapeutics (NASDAQ:XRTX)

XORTX Therapeutics (NASDAQ:XRTX) shares climbed 16.11% after hours following the announcement of a manufacturing milestone for its lead gout program, XRx-026. The company has begun production of drug material and tablets for XORLO™, its proprietary oxypurinol formulation, to support a planned two-part clinical study. This move is a foundational step towards a future New Drug Application (NDA) submission to the FDA.

Financial MarketsLife SciencesManufacturing
Published
16 Sep 2026 03:52
News subject
Market update
Why this score
Large positive market reaction, Positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 36/100
30-day weight
39.7% of the score · 9.3d old
Duplicates
1 consolidated
#7—Not directional
kalkine.caDirect company coverageScored from headline

XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis

Published
11 Sep 2026 18:13
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 13.7d old
Duplicates
1 consolidated
#8—Not directional
Market sourceDirect company coverageScored from headline

XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History

Published
11 Sep 2026 15:23
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 13.8d old
Duplicates
1 consolidated
#9—Not directional
GlobeNewswireDirect company coverageStored article

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

XORTX Therapeutics Inc. has started clinical and commercial manufacturing of XORLO™, its proprietary oxypurinol formulation for gout treatment. This production supports the upcoming XRX-OXY-102 clinical study and aims for future US FDA marketing approval. The company is advancing its XRx-026 program, which includes manufacturing GMP drug substance and commercial-scale tablets, and expects validation and stability data to support its New Drug Application filing.

Life SciencesManufacturing
Published
11 Sep 2026 09:11
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 14.1d old
Duplicates
1 consolidated
#10—Not directional
Stock TitanDirect company coverageStored article

XORTX Therapeutics (XRTX) begins making new gout drug

XORTX Therapeutics Inc. (XRTX) has initiated the manufacturing of XORLO, its proprietary oxypurinol formulation for gout, to support the planned XRX-OXY-102 clinical study and future FDA marketing application. This move is a strategic priority for the company, aiming to address the unmet needs in gout treatment where current oral xanthine oxidase inhibitors have limitations. The manufacturing efforts are expected to generate validation and stability data crucial for a New Drug Application (NDA) filing.

Life SciencesManufacturing
Published
10 Sep 2026 20:18
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 14.6d old
Duplicates
1 consolidated
#12—Not directional
markets.businessinsider.comDirect company coverageStored article

XORTX Re-Engages Investor Relations Program

XORTX Therapeutics Inc. has re-engaged IR Agency LLC for investor relations and marketing services following its voluntary delisting from the TSX Venture Exchange. The company, focused on developing treatments for gout, ADPKD, acute kidney injury, and diabetic nephropathy, aims to advance products targeting aberrant purine metabolism and xanthine oxidase. This re-engagement is under substantially similar terms to previously disclosed agreements, as XORTX continues to develop its pipeline of clinically advanced and pre-clinical stage programs.

FinanceLife Sciences
Published
09 Sep 2026 11:30
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.0d old
Duplicates
1 consolidated
#13—Not directional
Stock TitanDirect company coverageStored article

XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist

XORTX Therapeutics Inc. (XRTX) has re-engaged IR Agency LLC for investor relations and marketing services following its voluntary delisting from the TSX Venture Exchange. The three-month agreement, effective September 3, 2026, involves a US$2.5 million fee for up to ten news distribution campaigns, funded from previously returned fees from a terminated May 2026 agreement. This move aims to communicate company information to the financial community.

FinanceLife Sciences
Published
09 Sep 2026 03:52
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.3d old
Duplicates
1 consolidated
#14—Not directional
TradingViewDirect company coverageStored article

Price to sales forward of XORTX Therapeutics Inc. – NASDAQ:XRTX

The article focuses on XORTX Therapeutics Inc. (NASDAQ: XRTX) and its price to sales forward metric, as presented on TradingView. It appears to be a stub or a section of a larger financial data page, showing the company's stock market information and navigation links within the TradingView platform.

FinanceFinancial Markets
Published
09 Sep 2026 03:52
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.3d old
Duplicates
1 consolidated
#15—Not directional
Kalkine MediaDirect company coverageStored article

XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency

XORTX Therapeutics (NASDAQ: XRTX) has entered into a new $2.5 million investor relations agreement with IR Agency for marketing and news distribution services, effective September 3, 2026. This move follows the company's voluntary delisting from the TSXV and aims to enhance its presence on the Nasdaq Capital Market. The contract, which is non-refundable upon payment, explicitly states that IR Agency does not guarantee increased trading volume or stock price for XRTX.

FinanceFinancial MarketsLife Sciences
Published
08 Sep 2026 18:51
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.6d old
Duplicates
1 consolidated
#1657Tone
AD HOC NEWSDirect company coverageScored from headline

XORTX Therapeutics stock gains as Nasdaq listing takes center stage

Published
05 Sep 2026 12:05
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 28/100
30-day weight
0.5% of the score · 19.9d old
Duplicates
1 consolidated
#1971Tone
kalkine.caDirect company coverageStored article

XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum

XORTX Therapeutics (TSXV:XRTX) rose 4.59% on August 31, 2026, driven by increased investor interest in its kidney-disease pipeline and a sharper focus on capital preservation. The company's acquisition of an anti-fibrotic kidney asset and recent financing activities, coupled with the recovery of funds from a terminated investor-relations program, have strengthened its financial position. While the outlook is cautiously constructive, the company faces significant risks related to clinical execution, regulatory approval, and the capital-intensive nature of biotechnology development.

EarningsFinanceFinancial MarketsLife Sciences
Published
01 Sep 2026 07:54
News subject
Earnings
Why this score
Regulatory Approval
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 51/100
30-day weight
59.8% of the score · 24.1d old
Duplicates
1 consolidated
#20—Not directional
TipRanksDirect company coverageStored article

XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting

XORTX Therapeutics Inc. has terminated its investor relations agreement with IR Agency LLC, recovering a US$2.5 million prepaid fee. The company is postponing its marketing efforts and pursuing a voluntary delisting from the TSX Venture Exchange, effective September 1, 2026, to focus on business and clinical development. Additionally, XORTX corrected a prior disclosure regarding a US$240,000 finder's fee related to an acquisition.

EarningsFinanceLife Sciences
Published
29 Aug 2026 00:37
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 27.4d old
Duplicates
1 consolidated
#21—Not directional
Stock TitanDirect company coverageScored from headline

XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign

Published
28 Aug 2026 12:45
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 27.9d old
Duplicates
1 consolidated
#22—Not directional
GlobeNewswireDirect company coverageStored article

XORTX Announces Termination and Postponement of Investor Relations Program

XORTX Therapeutics Inc. has terminated its investor relations agreement with IR Agency LLC and postponed its marketing program. This decision was made to reduce regulatory complexity and focus resources while the company voluntarily delists from the TSX Venture Exchange, a process expected to complete by September 1, 2026. XORTX also disclosed finder's fees paid for a previous acquisition and announced a change in its transfer agent.

FinanceLife Sciences
Published
28 Aug 2026 07:00
News subject
Deals and strategy
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 28.1d old
Duplicates
1 consolidated
#23—Not directional
Value ResearchDirect company coverageScored from headline

XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others

Published
27 Aug 2026 20:01
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 28.6d old
Duplicates
1 consolidated
#24—Not directional
Value ResearchDirect company coverageScored from headline

XORTX Therapeutics Inc. (XRTX) Key Financial Ratios – Valuation, Profitability & More

Published
27 Aug 2026 20:01
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 28.6d old
Duplicates
1 consolidated

Earlier company news

XRTX news archive

37 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 37 older XRTX headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

3 not scored

A news provider linked these stories to XRTX, but the headline and available text are not mainly about XORTX Therapeutics Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of XRTX sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context